A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile. | Drug Discovery And Development ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: ...

Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position ...

An NHS trust’s leaders will this week be told that there have been “multiple outbreaks” and periods of increased incidence of ...

After tracking biosynthetic gene clusters in 86 adults for a year, researchers found that stable gene groups predict which ...

Acurx Pharmaceuticals (ACXP) stock jumped 218% after announcing a clinical trial for ibezapolstat, which showed 96% cure rate for C. difficile infection.

Scientists have identified why some gut microbes successfully stay in the gut after fecal transplants, while others are much more transient. The King's College London discovery could help make the ...

Acurx Pharmaceuticals Inc ACXP shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor reaction to ...